KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Amortization - Intangibles (2016 - 2025)

Pfizer (PFE) has disclosed Amortization - Intangibles for 17 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Amortization - Intangibles fell 11.26% to $1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.9 billion, a 8.26% decrease, with the full-year FY2025 number at $4.9 billion, down 7.79% from a year prior.
  • Amortization - Intangibles was $1.2 billion for Q4 2025 at Pfizer, up from $1.2 billion in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $1.4 billion in Q4 2024 to a low of $822.0 million in Q3 2022.
  • A 5-year average of $1.1 billion and a median of $1.2 billion in 2023 define the central range for Amortization - Intangibles.
  • Peak YoY movement for Amortization - Intangibles: crashed 62.47% in 2021, then skyrocketed 44.04% in 2023.
  • Pfizer's Amortization - Intangibles stood at $968.0 million in 2021, then decreased by 15.08% to $822.0 million in 2022, then surged by 54.14% to $1.3 billion in 2023, then grew by 9.39% to $1.4 billion in 2024, then fell by 11.26% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Amortization - Intangibles are $1.2 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.2 billion (Q2 2025).